权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Integrated ligand and target discovery by chemical proteomics for glioblastoma treatment.

通过化学蛋白质组学整合配体和靶点发现用于胶质母细胞瘤治疗。

基本信息

批准号：
10211553
负责人：
BENJAMIN F CRAVATT
金额：
$ 69.66万
依托单位：
STANFORD UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2021
资助国家：
美国
起止时间：
2021-07-01 至 2026-06-30
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10211553
关键词：
Address Adult Glioblastoma American Association of Cancer Research Astrocytes Automobile Driving Award Biochemical Biology Brain Caring Cell membrane Cells Chemicals Chemistry Clinical Clustered Regularly Interspaced Short Palindromic Repeats Data Dependence Development Epidermal Growth Factor Evolution Failure Frequencies Genes Genetic Heterogeneity Genomics Glioblastoma Growth Growth Factor Growth Factor Oncogenes Heterogeneity Human In Vitro Libraries Ligands Lipid Synthesis Pathway Malignant Neoplasms Malignant neoplasm of brain Medical Membrane Lipids Metabolic Methods Modeling Molecular Molecular Biology Molecular Target National Cancer Institute Patients Pharmaceutical Chemistry Pharmacology Pharmacopoeias Phenotype Plasma Play Positioning Attribute Program Development Protein Inhibition Proteins Proteomics Resistance Role Route Signal Transduction Stereotyping Structure Technology Thinness Validation Work activity-based protein profiling cancer type clinical risk clinically relevant drug candidate drug development effective therapy experimental study extrachromosomal DNA high risk in vivo induced pluripotent stem cell inhibitor/antagonist member neuro-oncology novel novel therapeutics overexpression particle screening small molecule libraries therapeutic target tumor tumor growth

项目摘要

PROJECT SUMMARY The epidermal growth factor (EGFR) oncogene is amplified and drives tumor growth in 55% of adult glioblastomas (GBMs). However, EGFR inhibitors have failed to demonstrate clinical benefit in GBM, presenting one of the most fundamental challenges facing the field of neuro-oncology. As highlighted by the National Cancer Institute’s recent think tank on progress in GBM, despite clear signals about the genomic underpinnings of GBM, including the high frequency of EGFR amplification, new drug development programs have stalled because of the high risk of clinical failures. Intra-tumoral genetic heterogeneity, and the poor brain-plasma ratios of many drug candidates, are thought to play a major role in clinical failure. Building on the team’s recent discoveries demonstrating that EGFR is amplified almost exclusively on extrachromosomal DNA particles (ecDNA), driving intra-tumoral genetic heterogeneity, accelerated tumor evolution, and EGFR inhibitor resistance, and their discovery of actionable metabolic dependencies that arise when EGFR becomes amplified, this proposal will identify proteins on which EGFR-amplified GBMs selectively depend for survival, even in highly heterogeneous tumors. This proposal integrates a hypothesis-driven approach with unbiased discovery using activity-based protein profiling (ABPP). In clinically relevant patient-derived models of GBM, this proposal takes a chemistry- first approach to discover both actionable dependencies that arise when EGFR is amplified and ligands that engage these proteins, which can be made to be highly brain-penetrant. By deploying fully functionalized (FF) small-molecule libraries to enable direct progression from phenotypic screening to target identification in living GBM cells, including in patient-derived GBMs with amplified EGFR, this proposal is poised to inform actionable therapeutic targets for patients in vivo. The proposed integrated approach provides a rapid route towards initiating new drug development that directly addresses the fundamental challenges of GBM.

项目总结